Éric Pichon

2.8k total citations
70 papers, 896 citations indexed

About

Éric Pichon is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Éric Pichon has authored 70 papers receiving a total of 896 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Pulmonary and Respiratory Medicine, 26 papers in Oncology and 12 papers in Surgery. Recurrent topics in Éric Pichon's work include Lung Cancer Treatments and Mutations (28 papers), Lung Cancer Diagnosis and Treatment (12 papers) and Myasthenia Gravis and Thymoma (12 papers). Éric Pichon is often cited by papers focused on Lung Cancer Treatments and Mutations (28 papers), Lung Cancer Diagnosis and Treatment (12 papers) and Myasthenia Gravis and Thymoma (12 papers). Éric Pichon collaborates with scholars based in France, United States and Germany. Éric Pichon's co-authors include Allen Tannenbaum, Sigurd Angenent, Éric Dansin, Marc Niethammer, Carl‐Fredrik Westin, Benjamin Besse, Julien Mazières, Gérard Zalcman, Guillermo Sapiro and Nicolas Girard and has published in prestigious journals such as Journal of Clinical Oncology, IEEE Transactions on Pattern Analysis and Machine Intelligence and Annals of Oncology.

In The Last Decade

Éric Pichon

62 papers receiving 866 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Éric Pichon France	16	356	261	147	145	121	70	896
Erini Makariou United States	17	119 0.3×	181 0.7×	252 1.7×	40 0.3×	127 1.0×	33	899
Jianbo Gao China	14	479 1.3×	374 1.4×	545 3.7×	69 0.5×	55 0.5×	57	1.2k
Naama Bogot Israel	19	515 1.4×	82 0.3×	548 3.7×	58 0.4×	71 0.6×	50	1.0k
Romain Modzelewski France	24	506 1.4×	198 0.8×	1.1k 7.6×	123 0.8×	36 0.3×	70	1.8k
Carlos López Spain	16	41 0.1×	267 1.0×	148 1.0×	226 1.6×	45 0.4×	67	1.2k
Albert Comelli Italy	23	382 1.1×	84 0.3×	710 4.8×	168 1.2×	37 0.3×	67	1.2k
J. Titano United States	14	294 0.8×	89 0.3×	746 5.1×	74 0.5×	58 0.5×	31	1.7k
Nicola H. Strickland United Kingdom	15	349 1.0×	76 0.3×	358 2.4×	23 0.2×	30 0.2×	43	928
Yongchang Zheng China	21	279 0.8×	330 1.3×	147 1.0×	109 0.8×	33 0.3×	78	1.4k

Countries citing papers authored by Éric Pichon

Since Specialization

Citations

This map shows the geographic impact of Éric Pichon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Éric Pichon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Éric Pichon more than expected).

Fields of papers citing papers by Éric Pichon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Éric Pichon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Éric Pichon. The network helps show where Éric Pichon may publish in the future.

Co-authorship network of co-authors of Éric Pichon

This figure shows the co-authorship network connecting the top 25 collaborators of Éric Pichon. A scholar is included among the top collaborators of Éric Pichon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Éric Pichon. Éric Pichon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gobbini, Élisa, Mamadou Diallo, Dominique Pasquier, et al.. (2025). Clinical characteristics and management of long survivors in extensive stage small cell lung cancer. Lung Cancer. 202. 108499–108499.

Cabart, Mathilde, Loı̈c Mourey, Sophie C. Schneider, et al.. (2024). Real-world overview of therapeutic strategies and prognosis of older patients with advanced or metastatic non-small cell lung cancer from the ESME database. Journal of Geriatric Oncology. 15(7). 101819–101819.

Léna, H., J. Cadranel, Nicolas Girard, et al.. (2023). 1404P Clinical characteristics and therapeutics sequences of KRAS G12C metastatic non-small cell lung cancer (mNCSLC) patients treated by sotorasib in the French pre-marketing authorization (MA) early access program (cohort temporary authorization of use, cATU). Annals of Oncology. 34. S803–S804. 1 indexed citations

Aparisi, Francisco, Enriqueta Felip, Éric Pichon, et al.. (2023). 1460P GALLANT-1: GB1211 galectin-3 (Gal-3) inhibitor plus atezolizumab (atz) for first line treatment in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC). Annals of Oncology. 34. S829–S830. 1 indexed citations

Pichon, Éric, et al.. (2022). Traitement par sotorasib en autorisation d’accès précoce dans le cancer pulmonaire non à petites cellules mutées KRAS G12C : expérience du centre hospitalier régional universitaire de Tours. Revue des Maladies Respiratoires. 40(1). 17–23. 2 indexed citations

Benítez, José Carlos, Marie‐Eve Boucher, Éric Dansin, et al.. (2021). Central Nervous System Metastases in Thymic Epithelial Tumors: A Brief Report of Real-World Insight From RYTHMIC. Journal of Thoracic Oncology. 16(12). 2144–2149. 1 indexed citations

Basse, Clémence, Angela Botticella, Thierry Jo Molina, et al.. (2021). RADIORYTHMIC: Phase III, Opened, Randomized Study of Postoperative Radiotherapy Versus Surveillance in Stage IIb/III of Masaoka Koga Thymoma after Complete Surgical Resection. Clinical Lung Cancer. 22(5). 469–472. 10 indexed citations

Flament, Thomas, et al.. (2020). Cross-Cultural Adaptation and Psychometric Validation of the French Version of the FAMCARE-Patient (FFP-16) Questionnaire for Outpatients With Advanced-Stage Cancer. Journal of Pain and Symptom Management. 60(1). 94–100.e1. 1 indexed citations

Péchoux, C. Le, N. Pourel, Fabrice Barlési, et al.. (2020). LBA3_PR An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: Primary end-point analysis of LungART (IFCT-0503, UK NCRI, SAKK) NCT00410683. Annals of Oncology. 31. S1178–S1178. 60 indexed citations

10.

Dansin, Éric, Laurent Mhanna, Laurent Greillier, et al.. (2018). Systemic Therapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort. Journal of Thoracic Oncology. 13(11). 1762–1770. 50 indexed citations

11.

Auliac, J.B., M. Pérol, David Planchard, et al.. (2018). P1.13-09 Efficacy and Tolerance of Osimertinib in Real Word Setting: Results of the French Early Access Program (EXPLORE T790M GFPC Study). Journal of Thoracic Oncology. 13(10). S585–S585. 1 indexed citations

12.

Ferreira, Marion, Éric Pichon, D. Carmier, et al.. (2018). Coronary Toxicities of Anti-PD-1 and Anti-PD-L1 Immunotherapies: a Case Report and Review of the Literature and International Registries. Targeted Oncology. 13(4). 509–515. 26 indexed citations

13.

Quoix, Élisabeth, Clarisse Audigier-Valette, A. Lavolé, et al.. (2018). Maintenance chemotherapy versus follow-up after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC): IFCT-1201 MODEL randomised phase III trial. Annals of Oncology. 29. viii744–viii745.

14.

Besse, Benjamin, Sylvestre Le Moulec, Julien Mazières, et al.. (2017). P2.06-024 Tedopi vs Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Advanced NSCLC Patients in a Phase 3, Randomized Trial: ATALANTE-1. Journal of Thoracic Oncology. 12(1). S1085–S1086. 1 indexed citations

15.

Guibert, Nicolas, Fabrice Barlési, R. Descourt, et al.. (2017). OA10.06 Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations (Biomarker IFCT Study). Journal of Thoracic Oncology. 12(1). S283–S283. 1 indexed citations

16.

Westeel, Virginie, Fabrice Barlési, J.J. Lafitte, et al.. (2017). Results of the phase III IFCT-0302 trial assessing minimal versus CT-scan-based follow-up for completely resected non-small cell lung cancer (NSCLC). Annals of Oncology. 28. v452–v452. 25 indexed citations

17.

Dansin, Éric, M. Kerjouan, Julien Mazières, et al.. (2017). P2.04-006 Updated Incidence of Thymic Epithelial Tumors (TET) in France and Clinical Presentation at Diagnosis. Journal of Thoracic Oncology. 12(1). S1000–S1000. 2 indexed citations

18.

Fiteni, Frédéric, Amélie Anota, Franck Bonnetain, et al.. (2016). Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy. European Respiratory Journal. 48(3). 861–872. 14 indexed citations

19.

Lemarié, Étienne, Laurent Vecellio, J. Hureaux, et al.. (2011). Aerosolized Gemcitabine in Patients with Carcinoma of the Lung: Feasibility and Safety Study. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 24(6). 261–270. 68 indexed citations

20.

Pichon, Éric, et al.. (2002). Towards Visually-Guided Neuromorphic Robots: Beobots. 71(4). 111–2; passim. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact